210 related articles for article (PubMed ID: 25359365)
1. The international serious adverse events consortium.
Holden AL; Contreras JL; John S; Nelson MR
Nat Rev Drug Discov; 2014 Nov; 13(11):795-6. PubMed ID: 25359365
[TBL] [Abstract][Full Text] [Related]
2. Managing the challenge of chemically reactive metabolites in drug development.
Park BK; Boobis A; Clarke S; Goldring CE; Jones D; Kenna JG; Lambert C; Laverty HG; Naisbitt DJ; Nelson S; Nicoll-Griffith DA; Obach RS; Routledge P; Smith DA; Tweedie DJ; Vermeulen N; Williams DP; Wilson ID; Baillie TA
Nat Rev Drug Discov; 2011 Apr; 10(4):292-306. PubMed ID: 21455238
[TBL] [Abstract][Full Text] [Related]
3. Virtual drug discovery with the rise of Chinese CROs.
Zhang MQ
Drug Discov Today; 2010 Sep; 15(17-18):693-7. PubMed ID: 20685343
[No Abstract] [Full Text] [Related]
4. Overtaking the DILI Model-T.
Opar A
Nat Rev Drug Discov; 2012 Aug; 11(8):585-6. PubMed ID: 22850771
[No Abstract] [Full Text] [Related]
5. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
Kaski JC
Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
[No Abstract] [Full Text] [Related]
7. Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity.
Fryburg DA
Drug Discov Today; 2010 Sep; 15(17-18):766-72. PubMed ID: 20599625
[TBL] [Abstract][Full Text] [Related]
8. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
Vallance P; Williams P; Dollery C
Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
[No Abstract] [Full Text] [Related]
9. Is being the first ever 'better' than being the best?
Luscombe E
Expert Opin Pharmacother; 2014 May; 15(7):i-ii. PubMed ID: 24666337
[No Abstract] [Full Text] [Related]
10. Editorial: The Innovative Medicines Initiative--collaborations are key to innovating R&D processes.
Laverty H; Goldman M
Biotechnol J; 2014 Sep; 9(9):1095-6. PubMed ID: 25174501
[No Abstract] [Full Text] [Related]
11. Requirements for a lead compound to become a clinical candidate.
Hefti FF
BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
[TBL] [Abstract][Full Text] [Related]
12. Competition: Unlikely partnerships.
Savage N
Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
[No Abstract] [Full Text] [Related]
13. Research institute and medical school to partner with international company in drug development venture.
W V Med J; 2014; 110(5):48. PubMed ID: 25643477
[No Abstract] [Full Text] [Related]
14. An industry perspective on drug target validation.
Jones LH
Expert Opin Drug Discov; 2016 Jul; 11(7):623-5. PubMed ID: 27111834
[No Abstract] [Full Text] [Related]
15. The clinical utility index as a practical multiattribute approach to drug development decisions.
Poland B; Hodge FL; Khan A; Clemen RT; Wagner JA; Dykstra K; Krishna R
Clin Pharmacol Ther; 2009 Jul; 86(1):105-8. PubMed ID: 19458614
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based lead discovery grows up.
Baker M
Nat Rev Drug Discov; 2013 Jan; 12(1):5-7. PubMed ID: 23274457
[No Abstract] [Full Text] [Related]
17. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.
Tweedie D; Polli JW; Berglund EG; Huang SM; Zhang L; Poirier A; Chu X; Feng B;
Clin Pharmacol Ther; 2013 Jul; 94(1):113-25. PubMed ID: 23588318
[TBL] [Abstract][Full Text] [Related]
18. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED; Van Dam J; Szalma S
Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
[No Abstract] [Full Text] [Related]
19. Collaborative virtual organisation and infrastructure for drug discovery.
Hardy B; Affentranger R
Drug Discov Today; 2013 Jul; 18(13-14):681-6. PubMed ID: 23416145
[TBL] [Abstract][Full Text] [Related]
20. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
